[Frontiers in Bioscience, Landmark, 20, 78-104, January 1, 2015]

The role of circulating microRNA in hepatocellular carcinoma

Simon Chang-Hao Tsao 1, 2 , Andreas Behren 2 , Jonathan Cebon 2 , Christopher Christophi 1

1The University of Melbourne, Department of Surgery Austin Health, Studley Road, Heidelberg, Victoria, Australia 3084, 2The Ludwig Institute for Cancer Research, Level 5, Olivia Newton-John Cancer and Wellness Centre, Austin Health, 145-163 Studley Road, Heidelberg, Victoria, Australia 3084


1. Abstract
2. Introduction
3. Search Strategy
4. Circulating miRNA
    4.1. miR-18a
      4.1.1. Tissue
      4.1.2. Serum
    4.2. miR-92a
      4.2.1. Tissue
      4.2.2. Serum
    4.3. miR-26a
      4.3.1. Tissue
      4.3.2. Serum
    4.4. miR-221
      4.4.1. Tissue
      4.4.2. Serum
    4.5. miR-224
      4.5.1. Tissue
      4.5.2. Serum
    4.6. miR-500
      4.6.1. Tissue
      4.6.2. Serum
    4.7. miR-885-5p
      4.7.1. Tissue
      4.7.2. Serum
    4.8. miR-15b, -130b
      4.8.1. Tissue
      4.8.2. Serum
    4.9. miR-21
      4.9.1. Tissue
      4.9.2. Serum
    4.10. miR-223
      4.10.1. Tissue
      4.10.2. Serum
    4.11. miR-122
      4.11.1. Tissue
      4.11.2. Serum
    4.12. miR-16
      4.12.1. Tissue
      4.12.2. Serum
    4.13. miR-195, -199a
      4.13.1. Tissue
      4.13.2. Serum
    4.14. miR-21, -26a, -27a, -122, -192, -223, -801
      4.14.1. Tissue
      4.14.2. Serum
    4.15. miR-25, -375, let-7f
      4.15.1. Tissue
      4.15.2. Serum
5. Discussion
6. Acknowledgement
7. References


Hepatocellular carcinoma (HCC) is a rapidly progressing disease that exerts a huge burden on patients and health care systems. Rapid progression and difficulty in detecting early disease are major obstacles in offering potentially curative treatments. Besides the lack of effective chemo- or immunotherapy for advanced disease, there are currently no reliable tumor markers or imaging technologies that can accurately diagnose early HCC or predict disease progression. Since the discovery of microRNA (miRNA) and its involvement in hepatocarcinogenesis, the literature describes their usefulness as potential new biomarkers and treatment targets. Some of these miRNAs can also be found in the systemic circulation. With advances in detection and sequencing technologies, an increasing amount of data demonstrate the possibility of using circulating miRNAs as biomarkers to improve our current management of HCC in a less-invasive manner. This paper will review circulating miRNAs with a known function in HCC, describing their role and function in tumorigenesis. This review discusses their potential use as biomarkers in conjunction with emerging treatments in the diagnosis and targeting of this disease.


1. A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward and D. Forman: Global cancer statistics. CA Cancer J Clin, 61(2), 69-90 (2011)
DOI: 10.3322/caac.20107

2. J. F. Perz, G. L. Armstrong, L. A. Farrington, Y. J. Hutin and B. P. Bell: The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol, 45(4), 529-38 (2006)
DOI: 10.1016/j.jhep.2006.05.013

3. G. Manghisi, Elba, S., Mossa, A., Giorgio, A., Aloisio, V., Perrotta, A., Tardio, B., Del Naja, C., Ca- turelli, E., Calandra, M., Castellano, L., De Sio, I., Capuano, G., Pomponi, D., Casti- glione, F., Cocchia, P., Farinati, F., Rinaldi, M., Adinolfi, L.E., Ragone, E., Felder, M., Zancanella, L., Pasquale, G., Stanzione, M., Marone, G., DAngelo, V., Gaeta, G.B., Giolitto, G., Lamborgese, B., Manzione, L., Russo, M., Colurcio, R., Vel- tri, E., Izzo, F: A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology, 28(3), 751-5 (1998)
DOI: 10.1002/hep.510280322

4. A. Budhu, H. L. Jia, M. Forgues, C. G. Liu, D. Goldstein, A. Lam, K. A. Zanetti, Q. H. Ye, L. X. Qin, C. M. Croce, Z. Y. Tang and X. W. Wang: Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology, 47(3), 897-907 (2008)
DOI: 10.1002/hep.22160

5. S. T. Fan, C. Mau Lo, R. T. Poon, C. Yeung, C. Leung Liu, W. K. Yuen, C. Ming Lam, K. K. Ng and S. Ching Chan: Continuous improvement of survival outcomes of resection of hepatocellular carcinoma: a 20-year experience. Ann Surg, 253(4), 745-58 (2011)
DOI: 10.1097/SLA.0b013e3182111195

6. J. Bruix, M. Sherman and A. A. f. t. S. o. L. D. Practice Guidelines Committee: Management of hepatocellular carcinoma. Hepatology, 42(5), 1208-36 (2005)
DOI: 10.1002/hep.20933

7. D. Cherqui, A. Laurent, N. Mocellin, C. Tayar, A. Luciani, J. T. Van Nhieu, T. Decaens, M. Hurtova, R. Memeo, A. Mallat and C. Duvoux: Liver resection for transplantable hepatocellular carcinoma: long-term survival and role of secondary liver transplantation. Ann Surg, 250(5), 738-46 (2009)
DOI: 10.1097/SLA.0b013e3181bd582b

8. L. Y. Yang, F. Fang, D. P. Ou, W. Wu, Z. J. Zeng and F. Wu: Solitary large hepatocellular carcinoma: a specific subtype of hepatocellular carcinoma with good outcome after hepatic resection. Ann Surg, 249(1), 118-23 (2009)
DOI: 10.1097/SLA.0b013e3181904988

9. R. S. Soong, M. C. Yu, K. M. Chan, H. S. Chou, T. J. Wu, C. F. Lee, T. H. Wu and W. C. Lee: Analysis of the recurrence risk factors for the patients with hepatocellular carcinoma meeting University of California San Francisco criteria after curative hepatectomy. World J Surg Oncol, 9, 9 (2011)
DOI: 10.1186/1477-7819-9-9

10. A. B. Benson, 3rd, T. A. Abrams, E. Ben-Josef, P. M. Bloomston, J. F. Botha, B. M. Clary, A. Covey, S. A. Curley, M. I. D’Angelica, R. Davila, W. D. Ensminger, J. F. Gibbs, D. Laheru, M. P. Malafa, J. Marrero, S. G. Meranze, S. J. Mulvihill, J. O. Park, J. A. Posey, J. Sachdev, R. Salem, E. R. Sigurdson, C. Sofocleous, J. N. Vauthey, A. P. Venook, L. W. Goff, Y. Yen and A. X. Zhu: NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw, 7(4), 350-91 (2009)

11. J. A. Marrero: Screening tests for hepatocellular carcinoma. Clin Liver Dis, 9(2), 235-51, vi (2005)

12. R. K. Sterling, E. C. Wright, T. R. Morgan, L. B. Seeff, J. C. Hoefs, A. M. Di Bisceglie, J. L. Dienstag and A. S. Lok: Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C. Am J Gastroenterol, 107(1), 64-74 (2012)
DOI: 10.1038/ajg.2011.312

13. X. Liu, Y. Cheng, W. Sheng, H. Lu, Y. Xu, Z. Long, H. Zhu and Y. Wang: Clinicopathologic features and prognostic factors in alpha-fetoprotein-producing gastric cancers: analysis of 104 cases. J Surg Oncol, 102(3), 249-55 (2010)
DOI: 10.1002/jso.21624

14. M. El-Bahrawy: Alpha-fetoprotein-producing non-germ cell tumours of the female genital tract. Eur J Cancer, 46(8), 1317-22 (2010)
DOI: 10.1016/j.ejca.2010.01.028

15. J. Bruix, M. Sherman and D. American Association for the Study of Liver: Management of hepatocellular carcinoma: an update. Hepatology, 53(3), 1020-2 (2011)
DOI: 10.1002/hep.24199

16. T. Behne and M. S. Copur: Biomarkers for hepatocellular carcinoma. Int J Hepatol, 2012, 859076 (2012)
DOI: 10.1155/2012/859076

17. G. Shiota and N. Miura: Biomarkers for hepatocellular carcinoma, Clinical Journal of Gastroenterology, 5(3), 177-182 (2012)

18. N. Iizuka, M. Oka, H. Yamada-Okabe, N. Mori, T. Tamesa, T. Okada, N. Takemoto, A. Tangoku, K. Hamada, H. Nakayama, T. Miyamoto, S. Uchimura and Y. Hamamoto: Comparison of gene expression profiles between hepatitis B virus- and hepatitis C virus-infected hepatocellular carcinoma by oligonucleotide microarray data on the basis of a supervised learning method. Cancer Res, 62(14), 3939-44 (2002)

19. M. Bellodi-Privato, M. S. Kubrusly, J. T. Stefano, I. C. Soares, A. Wakamatsu, A. C. Oliveira, V. A. Alves, T. Bacchella, M. C. Machado and L. A. D’Albuquerque: Differential gene expression profiles of hepatocellular carcinomas associated or not with viral infection. Braz J Med Biol Res, 42(12), 119-1127 (2009)

20. X. Chen, S. T. Cheung, S. So, S. T. Fan, C. Barry, J. Higgins, K. M. Lai, J. Ji, S. Dudoit, I. O. Ng, M. Van De Rijn, D. Botstein and P. O. Brown: Gene expression patterns in human liver cancers. Mol Biol Cell, 13(6), 1929-39 (2002)
DOI: 10.1091/mbc.02-02-0023.

21. D. P. Bartel: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 116(2), 281-97 (2004)
DOI: 10.1016/S0092-8674(04)00045-5

22. R. C. Lee, R. L. Feinbaum and V. Ambros: The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell, 75(5), 843-54 (1993)
DOI: 10.1016/0092-8674(93)90529-Y

23. W. Wu, M. Sun, G. M. Zou and J. Chen: MicroRNA and cancer: Current status and prospective. Int J Cancer, 120(5), 953-60 (2007)
DOI: 10.1002/ijc.22454

24. J. Yu, F. Wang, G. H. Yang, F. L. Wang, Y. N. Ma, Z. W. Du and J. W. Zhang: Human microRNA clusters: genomic organization and expression profile in leukemia cell lines. Biochem Biophys Res Commun, 349(1), 59-68 (2006)
DOI: 10.1016/j.bbrc.2006.07.207

25. R. N. Aravalli, C. J. Steer and E. N. Cressman: Molecular mechanisms of hepatocellular carcinoma. Hepatology, 48(6), 2047-63 (2008)
DOI: 10.1002/hep.22580

26. M. Negrini, M. Ferracin, S. Sabbioni and C. M. Croce: MicroRNAs in human cancer: from research to therapy. J Cell Sci, 120(Pt 11), 1833-40 (2007)
DOI: 10.1242/jcs.03450

27. L. He, J. M. Thomson, M. T. Hemann, E. Hernando-Monge, D. Mu, S. Goodson, S. Powers, C. Cordon-Cardo, S. W. Lowe, G. J. Hannon and S. M. Hammond: A microRNA polycistron as a potential human oncogene. Nature, 435(7043), 828-33 (2005)
DOI: 10.1038/nature03552

28. L. Gailhouste, L. Gomez-Santos and T. Ochiya: Potential applications of miRNAs as diagnostic and prognostic markers in liver cancer. Front Biosci (Landmark Ed), 18, 199-223 (2013)
DOI: 10.2741/4096

29. F. Borel, P. Konstantinova and P. L. Jansen: Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma. J Hepatol, 56(6), 1371-83 (2012)
DOI: 10.1016/j.jhep.2011.11.026

30. N. Kosaka, H. Iguchi and T. Ochiya: Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci, 101(10), 2087-92 (2010)
DOI: 10.1111/j.1349-7006.2010.01650.x

31. K. Wang, S. Zhang, B. Marzolf, P. Troisch, A. Brightman, Z. Hu, L. E. Hood and D. J. Galas: Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci U S A, 106(11), 4402-7 (2009)
DOI: 10.1073/pnas.0813371106

32. Y. Zhang, Y. Jia, R. Zheng, Y. Guo, Y. Wang, H. Guo, M. Fei and S. Sun: Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases. Clin Chem, 56(12), 1830-8 (2010)
DOI: 10.1373/clinchem.2010.147850

33. P. S. Mitchell, R. K. Parkin, E. M. Kroh, B. R. Fritz, S. K. Wyman, E. L. Pogosova-Agadjanyan, A. Peterson, J. Noteboom, K. C. O’Briant, A. Allen, D. W. Lin, N. Urban, C. W. Drescher, B. S. Knudsen, D. L. Stirewalt, R. Gentleman, R. L. Vessella, P. S. Nelson, D. B. Martin and M. Tewari: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A, 105(30), 10513-8 (2008)
DOI: 10.1073/pnas.0804549105

34. X. Chen, Y. Ba, L. Ma, X. Cai, Y. Yin, K. Wang, J. Guo, Y. Zhang, J. Chen, X. Guo, Q. Li, X. Li, W. Wang, Y. Zhang, J. Wang, X. Jiang, Y. Xiang, C. Xu, P. Zheng, J. Zhang, R. Li, H. Zhang, X. Shang, T. Gong, G. Ning, J. Wang, K. Zen, J. Zhang and C. Y. Zhang: Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res, 18(10), 997-1006 (2008)
DOI: 10.1038/cr.2008.282

35. C. Chen, D. A. Ridzon, A. J. Broomer, Z. Zhou, D. H. Lee, J. T. Nguyen, M. Barbisin, N. L. Xu, V. R. Mahuvakar, M. R. Andersen, K. Q. Lao, K. J. Livak and K. J. Guegler: Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res, 33(20), e179 (2005)
DOI: 10.1093/nar/gni178

36. L. Gailhouste and T. Ochiya: Cancer-related microRNAs and their role as tumor suppressors and oncogenes in hepatocellular carcinoma. Histol Histopathol, 28(4), 437-51 (2013)

37. Y. Murakami, T. Yasuda, K. Saigo, T. Urashima, H. Toyoda, T. Okanoue and K. Shimotohno: Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene, 25(17), 2537-45 (2006)
DOI: 10.1038/sj.onc.1209283

38. Y. Hayashita, H. Osada, Y. Tatematsu, H. Yamada, K. Yanagisawa, S. Tomida, Y. Yatabe, K. Kawahara, Y. Sekido and T. Takahashi: A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res, 65(21), 9628-32 (2005)
DOI: 10.1158/0008-5472.CAN-05-2352

39. E. Bandres, E. Cubedo, X. Agirre, R. Malumbres, R. Zarate, N. Ramirez, A. Abajo, A. Navarro, I. Moreno, M. Monzo and J. Garcia-Foncillas: Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer, 5, 29 (2006)
DOI: 10.1186/1476-4598-5-29

40. S. Volinia, G. A. Calin, C. G. Liu, S. Ambs, A. Cimmino, F. Petrocca, R. Visone, M. Iorio, C. Roldo, M. Ferracin, R. L. Prueitt, N. Yanaihara, G. Lanza, A. Scarpa, A. Vecchione, M. Negrini, C. C. Harris and C. M. Croce: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A, 103(7), 2257-61 (2006)
DOI: 10.1073/pnas.0510565103

41. C. W. Wu, Y. J. Dong, Q. Y. Liang, X. Q. He, S. S. Ng, F. K. Chan, J. J. Sung and J. Yu: MicroRNA-18a attenuates DNA damage repair through suppressing the expression of ataxia telangiectasia mutated in colorectal cancer. PLoS One, 8(2), e57036 (2013)
DOI: 10.1371/journal.pone.0057036

42. Y. Li, W. Tan, T. W. Neo, M. O. Aung, S. Wasser, S. G. Lim and T. M. Tan: Role of the miR-106b-25 microRNA cluster in hepatocellular carcinoma. Cancer Sci, 100(7), 1234-42 (2009)
DOI: 10.1111/j.1349-7006.2009.01164.x

43. E. Connolly, M. Melegari, P. Landgraf, T. Tchaikovskaya, B. C. Tennant, B. L. Slagle, L. E. Rogler, M. Zavolan, T. Tuschl and C. E. Rogler: Elevated expression of the miR-17-92 polycistron and miR-21 in hepadnavirus-associated hepatocellular carcinoma contributes to the malignant phenotype. Am J Pathol, 173(3), 856-64 (2008)
DOI: 10.2353/ajpath.2008.080096

44. H. Su, J. R. Yang, T. Xu, J. Huang, L. Xu, Y. Yuan and S. M. Zhuang: MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res, 69(3), 1135-42 (2009)
DOI: 10.1158/0008-5472.CAN-08-2886

45. W. H. Liu, S. H. Yeh, C. C. Lu, S. L. Yu, H. Y. Chen, C. Y. Lin, D. S. Chen and P. J. Chen: MicroRNA-18a prevents estrogen receptor-alpha expression, promoting proliferation of hepatocellular carcinoma cells. Gastroenterology, 136(2), 683-93 (2009)
DOI: 10.1053/j.gastro.2008.10.029

46. W. Wu, M. Takanashi, N. Borjigin, S. I. Ohno, K. Fujita, S. Hoshino, Y. Osaka, A. Tsuchida and M. Kuroda: MicroRNA-18a modulates STAT3 activity through negative regulation of PIAS3 during gastric adenocarcinogenesis. Br J Cancer, 108(3), 653-61 (2013)
DOI: 10.1038/bjc.2012.587

47. A. Francavilla, L. Polimeno, M. Barone, A. Azzarone and T. E. Starzl: Hepatic regeneration and growth factors. J Surg Oncol Suppl, 3, 1-7 (1993)
DOI: 10.1002/jso.2930530503

48. J. D. Yager, Jr.: Oral contraceptive steroids as promoters or complete carcinogens for liver in female Sprague-Dawley rats. Environ Health Perspect, 50, 109-12 (1983)
DOI: 10.1289/ehp.8350109

49. L. Chen, J. Zheng, Y. Zhang, L. Yang, J. Wang, J. Ni, D. Cui, C. Yu and Z. Cai: Tumor-specific expression of microRNA-26a suppresses human hepatocellular carcinoma growth via cyclin-dependent and -independent pathways. Mol Ther, 19(8), 1521-8 (2011)
DOI: 10.1038/mt.2011.64

50. L. Li, Z. Guo, J. Wang, Y. Mao and Q. Gao: Serum miR-18a: a potential marker for hepatitis B virus-related hepatocellular carcinoma screening. Dig Dis Sci, 57(11), 2910-6 (2012)
DOI: 10.1007/s10620-012-2317-y

51. L. M. Li, Z. B. Hu, Z. X. Zhou, X. Chen, F. Y. Liu, J. F. Zhang, H. B. Shen, C. Y. Zhang and K. Zen: Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res, 70(23), 9798-807 (2010)
DOI: 10.1158/0008-5472.CAN-10-1001

52. M. Shigoka, A. Tsuchida, T. Matsudo, Y. Nagakawa, H. Saito, Y. Suzuki, T. Aoki, Y. Murakami, H. Toyoda, T. Kumada, R. Bartenschlager, N. Kato, M. Ikeda, T. Takashina, M. Tanaka, R. Suzuki, K. Oikawa, M. Takanashi and M. Kuroda: Deregulation of miR-92a expression is implicated in hepatocellular carcinoma development. Pathol Int, 60(5), 351-7 (2010)
DOI: 10.1111/j.1440-1827.2010.02526.x

53. J. Kota, R. R. Chivukula, K. A. O’Donnell, E. A. Wentzel, C. L. Montgomery, H. W. Hwang, T. C. Chang, P. Vivekanandan, M. Torbenson, K. R. Clark, J. R. Mendell and J. T. Mendell: Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell, 137(6), 1005-17 (2009)
DOI: 10.1016/j.cell.2009.04.021

54. J. Ji, J. Shi, A. Budhu, Z. Yu, M. Forgues, S. Roessler, S. Ambs, Y. Chen, P. S. Meltzer, C. M. Croce, L. X. Qin, K. Man, C. M. Lo, J. Lee, I. O. Ng, J. Fan, Z. Y. Tang, H. C. Sun and X. W. Wang: MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med, 361(15), 1437-47 (2009)
DOI: 10.1056/NEJMoa0901282

55. X. Yang, L. Liang, X. F. Zhang, H. L. Jia, Y. Qin, X. C. Zhu, X. M. Gao, P. Qiao, Y. Zheng, Y. Y. Sheng, J. W. Wei, H. J. Zhou, N. Ren, Q. H. Ye, Q. Z. Dong and L. X. Qin: MicroRNA-26a suppresses tumor growth and metastasis of human hepatocellular carcinoma by targeting interleukin-6-Stat3 pathway. Hepatology, 58(1), 158-70 (2013)
DOI: 10.1002/hep.26305

56. H. B. El-Serag and K. L. Rudolph: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology, 132(7), 2557-76 (2007)
DOI: 10.1053/j.gastro.2007.04.061

57. I. O. Ng, M. M. Ng, E. C. Lai and S. T. Fan: Better survival in female patients with hepatocellular carcinoma. Possible causes from a pathologic approach. Cancer, 75(1), 18-22 (1995)
DOI: 10.1002/1097-0142(19950101)75:1<18::AID-CNCR2820750105>3.0.CO;2-#

58. K. Dohmen, H. Shigematsu, K. Irie and H. Ishibashi: Longer survival in female than male with hepatocellular carcinoma. J Gastroenterol Hepatol, 18(3), 267-72 (2003)
DOI: 10.1046/j.1440-1746.2003.02936.x

59. P. Tangkijvanich, V. Mahachai, P. Suwangool and Y. Poovorawan: Gender difference in clinicopathologic features and survival of patients with hepatocellular carcinoma. World J Gastroenterol, 10(11), 1547-50 (2004)

60. C. Lu and R. S. Kerbel: Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J Cell Biol, 120(5), 1281-8 (1993)
DOI: 10.1083/jcb.120.5.1281

61. A. Rabinovich, L. Medina, B. Piura, S. Segal and M. Huleihel: Regulation of ovarian carcinoma SKOV-3 cell proliferation and secretion of MMPs by autocrine IL-6. Anticancer Res, 27(1A), 267-72 (2007)

62. K. Malinowska, H. Neuwirt, I. T. Cavarretta, J. Bektic, H. Steiner, H. Dietrich, P. L. Moser, D. Fuchs, A. Hobisch and Z. Culig: Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor. Endocr Relat Cancer, 16(1), 155-69 (2009)
DOI: 10.1677/ERC-08-0174

63. F. R. Santer, K. Malinowska, Z. Culig and I. T. Cavarretta: Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells. Endocr Relat Cancer, 17(1), 241-53 (2010)
DOI: 10.1677/ERC-09-0200

64. W. E. Naugler, T. Sakurai, S. Kim, S. Maeda, K. Kim, A. M. Elsharkawy and M. Karin: Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science, 317(5834), 121-4 (2007)
DOI: 10.1126/science.1140485

65. S. Abiru, K. Migita, Y. Maeda, M. Daikoku, M. Ito, K. Ohata, S. Nagaoka, T. Matsumoto, Y. Takii, K. Kusumoto, M. Nakamura, A. Komori, K. Yano, H. Yatsuhashi, K. Eguchi and H. Ishibashi: Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis. Liver Int, 26(1), 39-45 (2006)
DOI: 10.1111/j.1478-3231.2005.01191.x

66. M. Soresi, L. Giannitrapani, F. D’Antona, A. M. Florena, E. La Spada, A. Terranova, M. Cervello, N. D’Alessandro and G. Montalto: Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma. World J Gastroenterol, 12(16), 2563-8 (2006)

67. W. Lou, Z. Ni, K. Dyer, D. J. Tweardy and A. C. Gao: Interleukin-6 induces prostate cancer cell growth accompanied by activation of stat3 signaling pathway. Prostate, 42(3), 239-42 (2000)
DOI: 10.1002/(SICI)1097-0045(20000215)42:3<239::AID-PROS10>3.0.CO;2-G

68. J. Bromberg and T. C. Wang: Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell, 15(2), 79-80 (2009)
DOI: 10.1016/j.ccr.2009.01.009

69. J. Zhou, L. Yu, X. Gao, J. Hu, J. Wang, Z. Dai, J. F. Wang, Z. Zhang, S. Lu, X. Huang, Z. Wang, S. Qiu, X. Wang, G. Yang, H. Sun, Z. Tang, Y. Wu, H. Zhu and J. Fan: Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol, 29(36), 4781-8 (2011)
DOI: 10.1200/JCO.2011.38.2697

70. S. A. Ciafre, S. Galardi, A. Mangiola, M. Ferracin, C. G. Liu, G. Sabatino, M. Negrini, G. Maira, C. M. Croce and M. G. Farace: Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem Biophys Res Commun, 334(4), 1351-8 (2005)
DOI: 10.1016/j.bbrc.2005.07.030

71. F. Gottardo, C. G. Liu, M. Ferracin, G. A. Calin, M. Fassan, P. Bassi, C. Sevignani, D. Byrne, M. Negrini, F. Pagano, L. G. Gomella, C. M. Croce and R. Baffa: Micro-RNA profiling in kidney and bladder cancers. Urol Oncol, 25(5), 387-92 (2007)
DOI: 10.1016/j.urolonc.2007.01.019

72. H. He, K. Jazdzewski, W. Li, S. Liyanarachchi, R. Nagy, S. Volinia, G. A. Calin, C. G. Liu, K. Franssila, S. Suster, R. T. Kloos, C. M. Croce and A. de la Chapelle: The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci U S A, 102(52), 19075-80 (2005)
DOI: 10.1073/pnas.0509603102

73. E. J. Lee, Y. Gusev, J. Jiang, G. J. Nuovo, M. R. Lerner, W. L. Frankel, D. L. Morgan, R. G. Postier, D. J. Brackett and T. D. Schmittgen: Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer, 120(5), 1046-54 (2007)
DOI: 10.1002/ijc.22394

74. L. Gramantieri, M. Ferracin, F. Fornari, A. Veronese, S. Sabbioni, C. G. Liu, G. A. Calin, C. Giovannini, E. Ferrazzi, G. L. Grazi, C. M. Croce, L. Bolondi and M. Negrini: Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res, 67(13), 6092-9 (2007)
DOI: 10.1158/0008-5472.CAN-06-4607

75. S. Galardi, N. Mercatelli, E. Giorda, S. Massalini, G. V. Frajese, S. A. Ciafre and M. G. Farace: miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J Biol Chem, 282(32), 23716-24 (2007)
DOI: 10.1074/jbc.M701805200

76. J. K. Gillies and I. A. Lorimer: Regulation of p27Kip1 by miRNA 221/222 in glioblastoma. Cell Cycle, 6(16), 2005-9 (2007)
DOI: 10.4161/cc.6.16.4526

77. C. le Sage, R. Nagel, D. A. Egan, M. Schrier, E. Mesman, A. Mangiola, C. Anile, G. Maira, N. Mercatelli, S. A. Ciafre, M. G. Farace and R. Agami: Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J, 26(15), 3699-708 (2007)
DOI: 10.1038/sj.emboj.7601790

78. Visone, L. Russo, P. Pallante, I. De Martino, A. Ferraro, V. Leone, E. Borbone, F. Petrocca, H. Alder, C. M. Croce and A. Fusco: MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer, 14(3), 791-8 (2007)
DOI: 10.1677/ERC-07-0129

79. F. Fornari, L. Gramantieri, M. Ferracin, A. Veronese, S. Sabbioni, G. A. Calin, G. L. Grazi, C. Giovannini, C. M. Croce, L. Bolondi and M. Negrini: MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. Oncogene, 27(43), 5651-61 (2008)
DOI: 10.1038/onc.2008.178

80. N. Felli, L. Fontana, E. Pelosi, R. Botta, D. Bonci, F. Facchiano, F. Liuzzi, V. Lulli, O. Morsilli, S. Santoro, M. Valtieri, G. A. Calin, C. G. Liu, A. Sorrentino, C. M. Croce and C. Peschle: MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. Proc Natl Acad Sci U S A, 102(50), 18081-6 (2005)
DOI: 10.1073/pnas.0506216102

81. L. Gramantieri, F. Fornari, M. Ferracin, A. Veronese, S. Sabbioni, G. A. Calin, G. L. Grazi, C. M. Croce, L. Bolondi and M. Negrini: MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. Clin Cancer Res, 15(16), 5073-81 (2009)
DOI: 10.1158/1078-0432.CCR-09-0092

82. A. Tannapfel, D. Grund, A. Katalinic, D. Uhlmann, F. Kockerling, U. Haugwitz, M. Wasner, J. Hauss, K. Engeland and C. Wittekind: Decreased expression of p27 protein is associated with advanced tumor stage in hepatocellular carcinoma. Int J Cancer, 89(4), 350-5 (2000)

DOI: 10.1002/1097-0215(20000720)89:4<350::AID-IJC6>3.0.CO;2-3

83. Y. Ito, T. Takeda, M. Sakon, M. Tsujimoto, M. Monden and N. Matsuura: Expression of p57/Kip2 protein in hepatocellular carcinoma. Oncology, 61(3), 221-5 (2001)
DOI: 10.1159/000055378

84. S. Nakai, T. Masaki, Y. Shiratori, T. Ohgi, A. Morishita, K. Kurokohchi, S. Watanabe and S. Kuriyama: Expression of p57(KIP2) in hepatocellular carcinoma: relationship between tumor differentiation and patient survival. Int J Oncol, 20(4), 769-75 (2002)

85. J. Li, Y. Wang, W. Yu, J. Chen and J. Luo: Expression of serum miR-221 in human hepatocellular carcinoma and its prognostic significance. Biochem Biophys Res Commun, 406(1), 70-3 (2011)
DOI: 10.1016/j.bbrc.2011.01.111

86. J. Luo, M. Chen, H. Huang, T. Yuan, M. Zhang, K. Zhang and S. Deng: Circulating microRNA-122a as a diagnostic marker for hepatocellular carcinoma. Onco Targets Ther, 6, 577-83 (2013)

87. Y. Wang and C. G. Lee: Role of miR-224 in hepatocellular carcinoma: a tool for possible therapeutic intervention? Epigenomics, 3(2), 235-43 (2011)
DOI: 10.2217/epi.11.5

88. Y. Ladeiro, G. Couchy, C. Balabaud, P. Bioulac-Sage, L. Pelletier, S. Rebouissou and J. Zucman-Rossi: MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology, 47(6), 1955-63 (2008)
DOI: 10.1002/hep.22256

89. Q. Li, G. Wang, J. L. Shan, Z. X. Yang, H. Z. Wang, J. Feng, J. J. Zhen, C. Chen, Z. M. Zhang, W. Xu, X. Z. Luo and D. Wang: MicroRNA-224 is upregulated in HepG2 cells and involved in cellular migration and invasion. J Gastroenterol Hepatol, 25(1), 164-71 (2010)
DOI: 10.1111/j.1440-1746.2009.05971.x

90. Y. Wang, A. T. Lee, J. Z. Ma, J. Wang, J. Ren, Y. Yang, E. Tantoso, K. B. Li, L. L. Ooi, P. Tan and C. G. Lee: Profiling microRNA expression in hepatocellular carcinoma reveals microRNA-224 up-regulation and apoptosis inhibitor-5 as a microRNA-224-specific target. J Biol Chem, 283(19), 13205-15 (2008)
DOI: 10.1074/jbc.M707629200

91. J. Secombe, S. B. Pierce and R. N. Eisenman: Myc: a weapon of mass destruction. Cell, 117(2), 153-6 (2004)
DOI: 10.1016/S0092-8674(04)00336-8

92. J. Gui, Y. Tian, X. Wen, W. Zhang, P. Zhang, J. Gao, W. Run, L. Tian, X. Jia and Y. Gao: Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies. Clin Sci (Lond), 120(5), 183-93 (2011)
DOI: 10.1042/CS20100297

93. A. M. Liu, T. J. Yao, W. Wang, K. F. Wong, N. P. Lee, S. T. Fan, R. T. Poon, C. Gao and J. M. Luk: Circulating miR-15b and miR-130b in serum as potential markers for detecting hepatocellular carcinoma: a retrospective cohort study. BMJ Open, 2(2), e000825 (2012)
DOI: 10.1136/bmjopen-2012-000825

94. Y. Yamamoto, N. Kosaka, M. Tanaka, F. Koizumi, Y. Kanai, T. Mizutani, Y. Murakami, M. Kuroda, A. Miyajima, T. Kato and T. Ochiya: MicroRNA-500 as a potential diagnostic marker for hepatocellular carcinoma. Biomarkers, 14(7), 529-38 (2009)
DOI: 10.3109/13547500903150771

95. C. T. Barry, M. D’Souza, M. McCall, S. Safadjou, C. Ryan, R. Kashyap, C. Marroquin, M. Orloff, A. Almudevar and T. E. Godfrey: Micro RNA expression profiles as adjunctive data to assess the risk of hepatocellular carcinoma recurrence after liver transplantation. Am J Transplant, 12(2), 428-37 (2012)
DOI: 10.1111/j.1600-6143.2011.03788.x

96. E. A. Afanasyeva, P. Mestdagh, C. Kumps, J. Vandesompele, V. Ehemann, J. Theissen, M. Fischer, M. Zapatka, B. Brors, L. Savelyeva, V. Sagulenko, F. Speleman, M. Schwab and F. Westermann: MicroRNA miR-885-5p targets CDK2 and MCM5, activates p53 and inhibits proliferation and survival. Cell Death Differ, 18(6), 974-84 (2011)
DOI: 10.1038/cdd.2010.164

97. L. Lin, Y. Lin, Y. Jin and C. Zheng: Microarray analysis of microRNA expression in liver cancer tissues and normal control. Gene, 523(2), 158-60 (2013)
DOI: 10.1016/j.gene.2013.02.055

98. A. Suetsugu, M. Nagaki, H. Aoki, T. Motohashi, T. Kunisada and H. Moriwaki: Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun, 351(4), 820-4 (2006)
DOI: 10.1016/j.bbrc.2006.10.128

99. S. Ma, T. K. Lee, B. J. Zheng, K. W. Chan and X. Y. Guan: CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene, 27(12), 1749-58 (2008)
DOI: 10.1038/sj.onc.1210811

100. S. Ma, K. W. Chan, L. Hu, T. K. Lee, J. Y. Wo, I. O. Ng, B. J. Zheng and X. Y. Guan: Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology, 132(7), 2542-56 (2007)
DOI: 10.1053/j.gastro.2007.04.025

101. S. Ma, K. H. Tang, Y. P. Chan, T. K. Lee, P. S. Kwan, A. Castilho, I. Ng, K. Man, N. Wong, K. F. To, B. J. Zheng, P. B. Lai, C. M. Lo, K. W. Chan and X. Y. Guan: miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell, 7(6), 694-707 (2010)
DOI: 10.1016/j.stem.2010.11.010

102. C. J. Guo, Q. Pan, D. G. Li, H. Sun and B. W. Liu: miR-15b and miR-16 are implicated in activation of the rat hepatic stellate cell: An essential role for apoptosis. J Hepatol, 50(4), 766-78 (2009)
DOI: 10.1016/j.jhep.2008.11.025

103. F. Meng, R. Henson, H. Wehbe-Janek, K. Ghoshal, S. T. Jacob and T. Patel: MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology, 133(2), 647-58 (2007)
DOI: 10.1053/j.gastro.2007.05.022

104. J. Xu, C. Wu, X. Che, L. Wang, D. Yu, T. Zhang, L. Huang, H. Li, W. Tan, C. Wang and D. Lin: Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog, 50(2), 136-42 (2011)
DOI: 10.1002/mc.20712

105. Q. W. Wong, R. W. Lung, P. T. Law, P. B. Lai, K. Y. Chan, K. F. To and N. Wong: MicroRNA-223 is commonly repressed in hepatocellular carcinoma and potentiates expression of Stathmin1. Gastroenterology, 135(1), 257-69 (2008)
DOI: 10.1053/j.gastro.2008.04.003

106. R. H. Yuan, Y. M. Jeng, H. L. Chen, P. L. Lai, H. W. Pan, F. J. Hsieh, C. Y. Lin, P. H. Lee and H. C. Hsu: Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma. J Pathol, 209(4), 549-58 (2006)
DOI: 10.1002/path.2011

107. J. Chang, E. Nicolas, D. Marks, C. Sander, A. Lerro, M. A. Buendia, C. Xu, W. S. Mason, T. Moloshok, R. Bort, K. S. Zaret and J. M. Taylor: miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1. RNA Biol, 1(2), 106-13 (2004)
DOI: 10.4161/rna.1.2.1066

108. H. Kutay, S. Bai, J. Datta, T. Motiwala, I. Pogribny, W. Frankel, S. T. Jacob and K. Ghoshal: Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem, 99(3), 671-8 (2006)
DOI: 10.1002/jcb.20982

109. H. Varnholt, U. Drebber, F. Schulze, I. Wedemeyer, P. Schirmacher, H. P. Dienes and M. Odenthal: MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology, 47(4), 1223-32 (2008)
DOI: 10.1002/hep.22158

110. W. C. Tsai, P. W. Hsu, T. C. Lai, G. Y. Chau, C. W. Lin, C. M. Chen, C. D. Lin, Y. L. Liao, J. L. Wang, Y. P. Chau, M. T. Hsu, M. Hsiao, H. D. Huang and A. P. Tsou: MicroRNA-122, a tumor suppressor microRNA that regulates intrahepatic metastasis of hepatocellular carcinoma. Hepatology, 49(5), 1571-82 (2009)
DOI: 10.1002/hep.22806

111. S. Bai, M. W. Nasser, B. Wang, S. H. Hsu, J. Datta, H. Kutay, A. Yadav, G. Nuovo, P. Kumar and K. Ghoshal: MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J Biol Chem, 284(46), 32015-27 (2009)
DOI: 10.1074/jbc.M109.016774

112. F. Fornari, L. Gramantieri, C. Giovannini, A. Veronese, M. Ferracin, S. Sabbioni, G. A. Calin, G. L. Grazi, C. M. Croce, S. Tavolari, P. Chieco, M. Negrini and L. Bolondi: MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res, 69(14), 5761-7 (2009)
DOI: 10.1158/0008-5472.CAN-08-4797

113. C. Coulouarn, V. M. Factor, J. B. Andersen, M. E. Durkin and S. S. Thorgeirsson: Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties. Oncogene, 28(40), 3526-36 (2009)
DOI: 10.1038/onc.2009.211

114. A. J. van der Meer, W. R. Farid, M. J. Sonneveld, P. E. de Ruiter, A. Boonstra, A. J. van Vuuren, J. Verheij, B. E. Hansen, R. J. de Knegt, L. J. van der Laan and H. L. Janssen: Sensitive detection of hepatocellular injury in chronic hepatitis C patients with circulating hepatocyte-derived microRNA-122. J Viral Hepat, 20(3), 158-66 (2013)
DOI: 10.1111/jvh.12001

115. H. Yamada, K. Suzuki, N. Ichino, Y. Ando, A. Sawada, K. Osakabe, K. Sugimoto, K. Ohashi, R. Teradaira, T. Inoue, N. Hamajima and S. Hashimoto: Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver. Clin Chim Acta, 424, 99-103 (2013)
DOI: 10.1016/j.cca.2013.05.021

116. O. F. Laterza, L. Lim, P. W. Garrett-Engele, K. Vlasakova, N. Muniappa, W. K. Tanaka, J. M. Johnson, J. F. Sina, T. L. Fare, F. D. Sistare and W. E. Glaab: Plasma MicroRNAs as sensitive and specific biomarkers of tissue injury. Clin Chem, 55(11), 1977-83 (2009)
DOI: 10.1373/clinchem.2009.131797

117. Q. Liu, H. Fu, F. Sun, H. Zhang, Y. Tie, J. Zhu, R. Xing, Z. Sun and X. Zheng: miR-16 family induces cell cycle arrest by regulating multiple cell cycle genes. Nucleic Acids Res, 36(16), 5391-404 (2008)
DOI: 10.1093/nar/gkn522

118. C. J. Guo, Q. Pan, B. Jiang, G. Y. Chen and D. G. Li: Effects of upregulated expression of microRNA-16 on biological properties of culture-activated hepatic stellate cells. Apoptosis, 14(11), 1331-40 (2009)
DOI: 10.1007/s10495-009-0401-3

119. K. Z. Qu, K. Zhang, H. Li, N. H. Afdhal and M. Albitar: Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol, 45(4), 355-60 (2011)
DOI: 10.1097/MCG.0b013e3181f18ac2

120. T. Xu, Y. Zhu, Y. Xiong, Y. Y. Ge, J. P. Yun and S. M. Zhuang: MicroRNA-195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells. Hepatology, 50(1), 113-21 (2009)
DOI: 10.1002/hep.22919

121. F. Fornari, M. Milazzo, P. Chieco, M. Negrini, G. A. Calin, G. L. Grazi, D. Pollutri, C. M. Croce, L. Bolondi and L. Gramantieri: MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res, 70(12), 5184-93 (2010)
DOI: 10.1158/0008-5472.CAN-10-0145

122. Q. H. Xie, X. X. He, Y. Chang, S. Z. Sun, X. Jiang, P. Y. Li and J. S. Lin: MiR-192 inhibits nucleotide excision repair by targeting ERCC3 and ERCC4 in HepG2.2.15 cells. Biochem Biophys Res Commun, 410(3), 440-5 (2011)
DOI: 10.1016/j.bbrc.2011.05.153

123. W. Li, L. Xie, X. He, J. Li, K. Tu, L. Wei, J. Wu, Y. Guo, X. Ma, P. Zhang, Z. Pan, X. Hu, Y. Zhao, H. Xie, G. Jiang, T. Chen, J. Wang, S. Zheng, J. Cheng, D. Wan, S. Yang, Y. Li and J. Gu: Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma. Int J Cancer, 123(7), 1616-22 (2008)
DOI: 10.1002/ijc.23693

124. F. Petrocca, R. Visone, M. R. Onelli, M. H. Shah, M. S. Nicoloso, I. de Martino, D. Iliopoulos, E. Pilozzi, C. G. Liu, M. Negrini, L. Cavazzini, S. Volinia, H. Alder, L. P. Ruco, G. Baldassarre, C. M. Croce and A. Vecchione: E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell, 13(3), 272-86 (2008)
DOI: 10.1016/j.ccr.2008.02.013

125. S. Ambs, R. L. Prueitt, M. Yi, R. S. Hudson, T. M. Howe, F. Petrocca, T. A. Wallace, C. G. Liu, S. Volinia, G. A. Calin, H. G. Yfantis, R. M. Stephens and C. M. Croce: Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res, 68(15), 6162-70 (2008)
DOI: 10.1158/0008-5472.CAN-08-0144

126. L. O’Connor, A. Strasser, L. A. O’Reilly, G. Hausmann, J. M. Adams, S. Cory and D. C. Huang: Bim: a novel member of the Bcl-2 family that promotes apoptosis. EMBO J, 17(2), 384-95 (1998)
DOI: 10.1093/emboj/17.2.384

127. M. Z. Xu, T. J. Yao, N. P. Lee, I. O. Ng, Y. T. Chan, L. Zender, S. W. Lowe, R. T. Poon and J. M. Luk: Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer, 115(19), 4576-85 (2009)
DOI: 10.1002/cncr.24495

128. A. M. Liu, R. T. Poon and J. M. Luk: MicroRNA-375 targets Hippo-signaling effector YAP in liver cancer and inhibits tumor properties. Biochem Biophys Res Commun, 394(3), 623-7 (2010)
DOI: 10.1016/j.bbrc.2010.03.036

129. X. X. He, Y. Chang, F. Y. Meng, M. Y. Wang, Q. H. Xie, F. Tang, P. Y. Li, Y. H. Song and J. S. Lin: MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo. Oncogene, 31(28), 3357-69 (2012)
DOI: 10.1038/onc.2011.500

130. B. K. Yoo, L. Emdad, Z. Z. Su, A. Villanueva, D. Y. Chiang, N. D. Mukhopadhyay, A. S. Mills, S. Waxman, R. A. Fisher, J. M. Llovet, P. B. Fisher and D. Sarkar: Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. J Clin Invest, 119(3), 465-77 (2009)
DOI: 10.1172/JCI36460

131. B. J. Reinhart, F. J. Slack, M. Basson, A. E. Pasquinelli, J. C. Bettinger, A. E. Rougvie, H. R. Horvitz and G. Ruvkun: The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature, 403(6772), 901-6 (2000)
DOI: 10.1038/35002607

132. A. E. Pasquinelli, B. J. Reinhart, F. Slack, M. Q. Martindale, M. I. Kuroda, B. Maller, D. C. Hayward, E. E. Ball, B. Degnan, P. Muller, J. Spring, A. Srinivasan, M. Fishman, J. Finnerty, J. Corbo, M. Levine, P. Leahy, E. Davidson and G. Ruvkun: Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature, 408(6808), 86-9 (2000)
DOI: 10.1038/35040556

133. A. Esquela-Kerscher and F. J. Slack: Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer, 6(4), 259-69 (2006)
DOI: 10.1038/nrc1840

134. A. E. Pasquinelli, A. McCoy, E. Jimenez, E. Salo, G. Ruvkun, M. Q. Martindale and J. Baguna: Expression of the 22 nucleotide let-7 heterochronic RNA throughout the Metazoa: a role in life history evolution? Evol Dev, 5(4), 372-8 (2003)
DOI: 10.1046/j.1525-142X.2003.03044.x

135. I. Bussing, F. J. Slack and H. Grosshans: let-7 microRNAs in development, stem cells and cancer. Trends Mol Med, 14(9), 400-9 (2008)
DOI: 10.1016/j.molmed.2008.07.001

136. S. M. Johnson, H. Grosshans, J. Shingara, M. Byrom, R. Jarvis, A. Cheng, E. Labourier, K. L. Reinert, D. Brown and F. J. Slack: RAS is regulated by the let-7 microRNA family. Cell, 120(5), 635-47 (2005)
DOI: 10.1016/j.cell.2005.01.014

137. J. Takamizawa, H. Konishi, K. Yanagisawa, S. Tomida, H. Osada, H. Endoh, T. Harano, Y. Yatabe, M. Nagino, Y. Nimura, T. Mitsudomi and T. Takahashi: Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res, 64(11), 3753-6 (2004)
DOI: 10.1158/0008-5472.CAN-04-0637

138. L. F. Sempere, M. Christensen, A. Silahtaroglu, M. Bak, C. V. Heath, G. Schwartz, W. Wells, S. Kauppinen and C. N. Cole: Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res, 67(24), 11612-20 (2007)
DOI: 10.1158/0008-5472.CAN-07-5019

139. S. Mi, J. Lu, M. Sun, Z. Li, H. Zhang, M. B. Neilly, Y. Wang, Z. Qian, J. Jin, Y. Zhang, S. K. Bohlander, M. M. Le Beau, R. A. Larson, T. R. Golub, J. D. Rowley and J. Chen: MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. Proc Natl Acad Sci U S A, 104(50), 19971-6 (2007)
DOI: 10.1073/pnas.0709313104

140. S. Shimizu, T. Takehara, H. Hikita, T. Kodama, T. Miyagi, A. Hosui, T. Tatsumi, H. Ishida, T. Noda, H. Nagano, Y. Doki, M. Mori and N. Hayashi: The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma. J Hepatol, 52(5), 698-704 (2010)
DOI: 10.1016/j.jhep.2009.12.024

141. J. Torrisani, B. Bournet, M. C. du Rieu, M. Bouisson, A. Souque, J. Escourrou, L. Buscail and P. Cordelier: let-7 MicroRNA transfer in pancreatic cancer-derived cells inhibits in vitro cell proliferation but fails to alter tumor progression. Hum Gene Ther, 20(8), 831-44 (2009)
DOI: 10.1089/hum.2008.134

142. P. Shapiro: Ras-MAP kinase signaling pathways and control of cell proliferation: relevance to cancer therapy. Crit Rev Clin Lab Sci, 39(4-5), 285-330 (2002)
DOI: 10.1080/10408360290795538

143. J. L. Bos: ras oncogenes in human cancer: a review. Cancer Res, 49(17), 4682-9 (1989)

144. S. Liang, L. He, X. Zhao, Y. Miao, Y. Gu, C. Guo, Z. Xue, W. Dou, F. Hu, K. Wu, Y. Nie and D. Fan: MicroRNA let-7f inhibits tumor invasion and metastasis by targeting MYH9 in human gastric cancer. PLoS One, 6(4), e18409 (2011)
DOI: 10.1371/journal.pone.0018409

145. N. B. Tsui, E. K. Ng and Y. M. Lo: Stability of endogenous and added RNA in blood specimens, serum, and plasma. Clin Chem, 48(10), 1647-53 (2002)

Abbreviations: ADAM: A disintegrin and metalloprotease; AEG-1: Astrocyte elevated gene-1; AFP: Alpha-fetoprotein; AFP-L3: AFP Lens culinaris agglutinin-reactive fraction; API-5: Apoptosis inhibitor 5; AUC: Area under the operating characteristic curve; CD1: Cyclin D1; CDK2: Cyclin-dependent kinase 2; CDK6: Cyclin-dependent kinase 6, CTC: Circulating tumor cell, DCP: Des-gamma-carboxyprothrombin; EMT: Epithelial to mesenchymal transition; ERα: Estrogen receptor alpha; ESR1: Estrogen receptor 1; HBV: Hepatitis B virus; HCC: Hepatocellular Carcinoma; HCV: Hepatitis C virus; HSC: Hepatic stellate cells; IGF-1: Insulin like growth factor 1; IGF1R: Insulin-like growth factor 1 receptor; Let-7: Lethal-7; MCM5: mini-chromosome maintenance protein; MCM7: minichromosome maintenance protein 7; mTOR: Mammalian target of rapamycin; PIAS3: Protein Inhibitor of Activated Signal Transducer and Activator of Transcription 3; PTEN: Phosphatase and tensin homolog; SRF: Serum response factor; STAT: Signal transducer and activator of transcription; STAT3: Signal Transducer and Activator of Transcription 3; STMN1: Stathmin 1; VEGF: Vascular endothelial growth factor; YAP: Yes-associated protein.

Key Words: MicroRNA, Serum microRNA, Circulating microRNA, Hepatocellular carcinoma, HCC, Prognosis, Diagnosis, Therapy, Treatment, Review

Send correspondence to: Christopher Christophi, The University of Melbourne, Department of Surgery Austin Health Studley Road, Heidelberg, Victoria, Australia 3084. Tel:613-9496-5468, Fax: 613-945-8650, E-mail: c.christophi@unimelb.edu.au